Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose–response study

por Singh, Dave, Boyce, Malcolm, Norris, Virginia, Kent, Sandra E, Bentley, Jane H
Publicado 2013

Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome

por Pane, Fabrizio, Lefevre, Guillaume, Kwon, Namhee, Bentley, Jane H., Yancey, Steven W., Steinfeld, Jonathan
Publicado 2022

The Pharmacokinetics and Relative Bioavailability of Mepolizumab 100 mg Liquid Formulation Administered Subcutaneously to Healthy Participants: A Randomized Trial

por Shabbir, Shaila, Pouliquen, Isabelle J., Bentley, Jane H., Bradford, Eric S., C. Kaisermann, Morrys, Albayaty, Muna
Publicado 2019

Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome

por Roufosse, Florence, Butterfield, Joseph, Steinfeld, Jonathan, Bentley, Jane H., von Maltzahn, Robyn, Kwon, Namhee, Nelsen, Linda
Publicado 2023

Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype

por Terrier, Benjamin, Jayne, David R.W., Hellmich, Bernhard, Bentley, Jane H., Steinfeld, Jonathan, Yancey, Steven W., Kwon, Namhee, Akuthota, Praveen, Khoury, Paneez, Baylis, Lee, Wechsler, Michael E.
Publicado 2023

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial

por Roufosse, Florence, Kahn, Jean-Emmanuel, Rothenberg, Marc E., Wardlaw, Andrew J., Klion, Amy D., Kirby, Suyong Yun, Gilson, Martyn J., Bentley, Jane H., Bradford, Eric S., Yancey, Steven W., Steinfeld, Jonathan, Gleich, Gerald J.
Publicado 2020